Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $12.20 $16.47 Friday, 10th May 2024 VRDN stock ended at $13.90. This is 0.0719% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 5.32% from a day low at $13.34 to a day high of $14.05.
90 days $12.20 $21.42
52 weeks $10.93 $28.35

Historical Viridian Therapeutics, Inc. prices

Date Open High Low Close Volume
Feb 29, 2024 $20.86 $20.95 $18.56 $18.71 1 061 966
Feb 28, 2024 $19.52 $21.42 $18.67 $20.17 1 883 225
Feb 27, 2024 $19.48 $19.98 $18.60 $19.61 748 425
Feb 26, 2024 $18.77 $19.75 $18.51 $19.27 566 347
Feb 23, 2024 $18.02 $19.12 $17.64 $18.77 580 497
Feb 22, 2024 $19.27 $19.27 $17.97 $17.99 514 338
Feb 21, 2024 $19.27 $19.46 $18.18 $18.52 549 479
Feb 20, 2024 $18.47 $19.26 $18.14 $19.23 783 983
Feb 16, 2024 $18.95 $19.24 $18.49 $18.59 884 530
Feb 15, 2024 $18.48 $19.38 $18.31 $19.23 777 205
Feb 14, 2024 $18.12 $18.68 $17.56 $18.31 1 171 524
Feb 13, 2024 $18.78 $18.81 $17.52 $17.74 985 864
Feb 12, 2024 $18.60 $19.70 $18.50 $19.68 662 970
Feb 09, 2024 $18.22 $18.96 $17.84 $18.52 638 193
Feb 08, 2024 $17.82 $18.49 $17.04 $17.96 697 269
Feb 07, 2024 $18.48 $18.48 $17.40 $17.74 820 701
Feb 06, 2024 $18.62 $18.80 $18.32 $18.49 743 858
Feb 05, 2024 $18.57 $18.83 $18.19 $18.70 884 470
Feb 02, 2024 $19.59 $19.82 $18.73 $18.85 810 548
Feb 01, 2024 $19.45 $20.44 $19.26 $20.00 1 017 971
Jan 31, 2024 $19.50 $20.03 $19.19 $19.25 650 573
Jan 30, 2024 $20.20 $20.20 $19.41 $19.54 768 422
Jan 29, 2024 $19.93 $20.50 $19.60 $20.35 643 476
Jan 26, 2024 $20.06 $20.38 $19.60 $19.89 816 013
Jan 25, 2024 $19.77 $20.09 $19.28 $19.68 1 013 863
Click to get the best stock tips daily for free!

About Viridian Therapeutics, Inc.

Viridian Therapeutics. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ... VRDN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT